Last update 01 Nov 2024

Changzhou Jimu Biotechnology Co., Ltd.

Private Company|
2012|
Jiangsu Sheng, China

Overview

Tags

Eye Diseases
Nervous System Diseases
Mouth and Tooth Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
mAChRs(Muscarinic acetylcholine receptor)2

Related

2
Drugs associated with Changzhou Jimu Biotechnology Co., Ltd.
Atropine Sulfate
Target
mAChRs
Mechanism
mAChRs antagonists
Active Org.
Bausch & Lomb, Inc.Bausch & Lomb, Inc. [+36]
Originator Org.
Santen Pharmaceutical Co., Ltd.Santen Pharmaceutical Co., Ltd.
Active Indication
Myopia [+11]
Inactive Indication
Organophosphate Poisoning
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date20 Jul 1968
Pilocarpine Hydrochloride
Target
mAChRs
Mechanism
mAChRs agonists
Active Org.
AbbVie, Inc.AbbVie, Inc. [+13]
Originator Org.
Alcon Canada, Inc.Alcon Canada, Inc.
Active Indication
Presbyopia [+3]
Inactive Indication
Kerato conjunctivitis sicca
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CA
First Approval Date31 Dec 1951
5
Clinical Trials associated with Changzhou Jimu Biotechnology Co., Ltd.
CTR20222349 / RecruitingPhase 3
硫酸阿托品微量眼用溶液(ARVN002)延缓儿童近视进展的有效性和安全性的随机、双盲、安慰剂对照、多中心III期临床研究
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase III clinical study on the efficacy and safety of atropine sulfate ophthalmic solution (ARVN002) in delaying the progression of myopia in children
CTR20221337 / RecruitingPhase 3
老视患者使用微量给药器给予ARVN003以暂时性改善近视力的有效性和安全性的随机、多中心、双盲、安慰剂对照、III期临床研究
[Translation] A randomized, multicenter, double-blind, placebo-controlled, phase III clinical study on the efficacy and safety of ARVN003 in temporarily improving near vision in patients with presbyopia using a micro-dose applicator
CTR20212691 / RecruitingPhase 1
一项评估曲安奈德脉络膜上腔注射混悬液（ARVN001） 在糖尿病性黄斑水肿患者中的安全耐受性、 药代动力学特征及初步疗效的多中心、 开放、单臂的 I 期临床研究
[Translation] A multicenter, open-label, single-arm Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of triamcinolone acetonide suprachoroidal injection suspension (ARVN001) in patients with diabetic macular edema
100 Clinical Results associated with Changzhou Jimu Biotechnology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Changzhou Jimu Biotechnology Co., Ltd.
Login to view more data
100 Deals associated with Changzhou Jimu Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Changzhou Jimu Biotechnology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 3 Clinical
2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Atropine Sulfate
 ( mAChRs )		Myopia
More
Phase 3
Pilocarpine Hydrochloride
 ( mAChRs )		Presbyopia
More
Phase 3
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free